PharmacoMicrobiomics: The Drug-Microbiome Portal

How Bugs Modulate Drugs?

Launched on 11/11/11; Current Release 1.5 (21 Mar 2021): Spring of Hope! (Release History)

Welcome To PharmacoMicrobiomics!

The PharmacoMicrobiomics web portal is a part of an initiative to explore the interactions between human-associated microbes (human microbiome) and drugs by building a knowledgebase that allows interested students and investigators "to predict the behavior of untested members of drug classes or unstudied microbial species, and to design laboratory experiments for testing these predictions. (More in BMC Bioinformatics 2011, 12(Suppl 7):A10)



What to Find Here?

You will be able to find different types of information mostly related to the effect of microbes on drugs (more specifically on the effect of human microbiota on drug disposition or pharmacokinetics). In the future, there may be more information about more complex drug-microbe interactions, and about microbes as drugs, drug factories, or drug-delivery vehicles.


You now can find several entries in the database, including:

You can also find more entries still in "draft" format (mostly Google Docs) that describe a long reading/task list for our current or future curators, and also for those community volunteers who are willing to join our efforts.


Random Interaction

Gut
Chloroquine (2719)
Bacteria (2)
33964992
(Year: 2021)
increase toxicity
Possibilities of interaction between traditional herbs and antiviral drugs that used to treat Covid when used in combinations. Traditional Chinese herbs that contain glycoside need to be hydrolyzed by glycosidase in the gut microbiota to more bioavailable and pharmacologically active aglycone like: Polydatin -- B-glucosidase ----> Resveratrol Geniposide -- B-glucosidase ----> Genipin Quercetrin -- α-rhamnosidase--->Quercetin Glycyrrhizin-- B-glucuronidase--> Glycyrrhetinic acid Antiviral drugs (lopinavir, ritonavir, chloroquine, darunavir, ribavirin, arbidol, favipiravir, oseltamivir) could change microbiota composition and its enzyme thereby, inhibiting Chinese medicine activation and leading to toxic product accumulation. Results between 1 to 4 hours of Chloroquine taking aglycon part of negative control as 100% to normalize the concentration: No significant reduction in resveratrol. Chloroquine reduces genipin significantly P<0.05 by more than 80%. Chloroquine reduces quercetin significantly P<0.05 by more than 70%. No significant reduction in Glycyrrhetinic acid. In vitro inhibition of bacterial β-glucosidase, α-rhamnosidase and β-glucuronidase by chloroquine: chloroquine shows a weak inhibitory effect on β-glucosidase and no inhibition on α-rhamnosidase. (See record)


Credits

This drug-microbiome database was designed and built as the graduation project of the Open Source Technologies track at the Information Technology Institute (ITI) in June, 2011.

Django, the Python-based framework, was used to build the web portal, and JQuery libraries. JLinkPreview plugin is provided by Sarpdoruk Tahmaz. This template is distributed under a Creative Commons Attribution 2.5 License by Arcsin Web Templates. The project was hosted by WebFaction (2011-2021). It is currently hosted by Digital Ocean.